The High Court of Delhi has temporarily stopped a drug company from making or selling a generic medicine for nausea caused by chemotherapy, after the holders of a patent on the drug combination said the product copies their invention. The order, passed on 10 November 2026, is an interim one. It lasts only until the next hearing and does not decide the patent suit.

Justice Manmeet Pritam Singh Arora passed the order in Helsinn Healthcare SA & Anr. v. Intas Pharmaceutical Limited, CS(COMM) 1219/2026. The Court grants an ad-interim injunction, which is a short-term restraint given at the very start of a case to keep matters as they are until both sides are fully heard.

What the dispute is about

A patent is the exclusive legal right over an invention for a limited period. The first plaintiff, a pharmaceutical group incorporated in Switzerland, owns Indian Patent No. 426553. The second plaintiff is an Indian company and the exclusive licensee, meaning the firm permitted to use the patent. The patent was granted on 23 March 2023 and is stated to be valid until 18 November 2030.

The patent relates to a dose taken by mouth that combines two substances, Netupitant and Palonosetron, to treat nausea and vomiting brought on by chemotherapy. The plaintiffs sell their version under the brand name AKYNZEO, which was launched in India in May 2018.

The plaintiffs say that on 7 November 2026 they learnt through a market surveyor that the defendant was preparing to launch a generic product under the name NO-CINV. Photographs showed a combipack, a single pack holding two separate tablets: Netupitant 300 mg and Palonosetron 0.5 mg. They sent a notice the same day asking the defendant to undertake not to infringe, received no response, and approached the Court on 9 November 2026.

What the defendant argued

Senior counsel for the defendant told the Court that the product had already been launched countrywide on 7 November 2026. He handed over three invoices showing dispatches to two buyers, with a total of approximately Rs. 14 lakhs, and asked for a chance to file a written response before any restraint was considered.

He also argued that the separate patents on each of the two substances have expired, so both are known substances, and that merely combining two known substances cannot be treated as an invention. On that basis, he said, the patent is open to challenge for lack of novelty, meaning that it claims nothing new. He admitted, however, that the defendant has not instituted any legal proceedings challenging the validity of the patent.

The Court's reasons

The Court finds that the defendant's product contains the same two substances, packaged together to be taken by mouth. It records:

The infringement of the Claims 1 to 4 of the suit patent is thus prima facie evident and is not contested by the Defendant during arguments.

Prima facie means on a first look, before a full hearing. The Court relies on an earlier order of the same High Court, dated 30 April 2024, in a case against Hetero Healthcare Limited, where a combipack of the same two substances was restrained. The Court says the facts here are alike.

On the challenge to the patent, the Court notes that the patent was granted after two pre-grant oppositions by other companies were considered and rejected. The defendant, an established pharmaceutical company, knew of the patent and still did not use the legal remedies available to challenge it before launching. The Court calls this a failure to clear the way, and says:

The Defendant has taken a calculated commercial risk in proceeding to manufacture the impugned product without first clearing the way and must therefore await adjudication of the merit of its defence plea.

The Court holds that the novelty argument needs a detailed study of the patent documents and the patent office orders. That can be done only after both sides file their written cases, not on the first day of listing. Since the product was launched only recently, the Court finds a short restraint will cause the defendant no prejudice, while the plaintiffs are likely to suffer irreparable harm without it.

What the order directs

  • Until the next hearing, the defendant and its directors, employees, agents, distributors and stockists are restrained from manufacturing, using, selling, offering for sale, distributing, advertising, exporting or otherwise dealing in NO-CINV or any other product that infringes the patent.
  • The defendant must file its reply on or before 17 November 2026, with the invoices for goods sold between 7 November 2026 and 10 November 2026 and airway bills proving dispatch and delivery.
  • The defendant must also disclose its existing stock as on 10 November 2026, with batch numbers and dates of manufacture and expiry, in a pleading signed by a Director.
  • The plaintiffs must pay the court fees on or before 20 November 2026, failing which the plaint will be liable to be rejected.
  • The plaintiffs are exempted from pre-litigation mediation, a settlement step usually required before a commercial suit, because urgent interim relief is sought.

The Court adds a caution about the limits of its order: "The observations herein, however, are only prima facie". The defendant keeps its right to raise all permissible defences. The matter is listed before the Roster Bench on 17 November 2026.